(Q43672627)

25 November 2017

title

An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer (English)

1 reference

25 November 2017

1 reference

Wright JC

1

1 reference

25 November 2017

Tao Leonard S

2

1 reference

25 November 2017

Stevenson CL

3

1 reference

25 November 2017

Beck JC

4

1 reference

25 November 2017

Chen G

5

1 reference

25 November 2017

Jao RM

6

1 reference

25 November 2017

Johnson PA

7

1 reference

25 November 2017

Leonard J

8

1 reference

25 November 2017

Skowronski RJ

9

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

Journal of Controlled Release

25 November 2017

published in

1 reference

25 November 2017

volume

75

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

1-10

1 reference

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

Effect of gelation on the chemical stability and conformation of leuprolide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900358-3

7 January 2021

10.1016/S0168-3659(01)00358-3

Identifiers

DOI

1 reference

25 November 2017

1 reference